Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Marketed plasma-derived VWF/FVIII · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII) | BIOLOGICAL | Single dose, dose escalation, various cohorts |
| Marketed plasma-derived VWF/FVIII concentrate | BIOLOGICAL | Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate |
Inclusion Criteria: * Subject has voluntarily given written informed consent (before conduct of any study-related procedures) * The subject has hereditary type 3 VWD (\<= 3 IU/dL VWF:Ag)or severe type 1 or type 2A VWD (VWF:RCo \<= 10% and FVIII:C \<20%) * The subject has a medical history of at lea...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Vonicog Alfa, ADVATE |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE2 | ALN-6400 |
| Hemab Therapeutics Holdings, Inc. | COAG | 2 | PHASE1 | HMB-002 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | - | Undisclosed |
Marketed plasma-derived VWF/FVIII is used for the treatment of Von Willebrand Disease, a bleeding disorder. It is being developed by Takeda Pharmaceutical Company Limited and is currently in Phase 1 clinical development.
Marketed plasma-derived VWF/FVIII is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is being studied for the treatment of Von Willebrand Disease.
Marketed plasma-derived VWF/FVIII is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
Marketed plasma-derived VWF/FVIII has one completed Phase 1 trial, NCT00816660, which studied the pharmacokinetics, safety, and tolerability of the drug in patients with Type 3 Von Willebrand Disease. The trial enrolled 32 participants across the United States, Austria, Canada, Germany, Italy, and the United Kingdom.
Marketed plasma-derived VWF/FVIII is classified as a monoclonal antibody modality. It is being developed for the treatment of Von Willebrand Disease and is currently in Phase 1 clinical trials.